Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.73AUD
18 Oct 2017
Change (% chg)

$-0.02 (-1.14%)
Prev Close
$1.75
Open
$1.74
Day's High
$1.80
Day's Low
$1.73
Volume
823,153
Avg. Vol
845,284
52-wk High
$3.41
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment
Thursday, 28 Sep 2017 06:00am EDT 

Sept 28 (Reuters) - Mesoblast Ltd :Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment.  Full Article

Mesoblast posts FY loss attributable of $76.8 mln
Tuesday, 29 Aug 2017 05:31pm EDT 

Aug 30 (Reuters) - Mesoblast Ltd ::FY total revenue $2.4 million versus $42.5 million .FY loss attributable to owners of co $76.8 million versus loss of $4.1 million.  Full Article

Mesoblast completes institutional entitlement offer for capital raise
Monday, 28 Aug 2017 08:13pm EDT 

Aug 29 (Reuters) - Mesoblast Ltd :Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise.New shares in Mesoblast will be issued at a price of A$1.40 per new share (offer price) on a 1 for 12 pro-rata basis.  Full Article

Mesoblast announces capital raising
Thursday, 24 Aug 2017 08:53pm EDT 

Aug 25 (Reuters) - Mesoblast Ltd :Fully underwritten accelerated non-renounceable entitlement offer to raise A$50.7m.Entitlement offer will be at an offer price of A$1.40 per new share.  Full Article

Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares
Monday, 10 Jul 2017 09:38am EDT 

July 10 (Reuters) - Mesoblast Ltd ::Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares .  Full Article

Mesoblast says qtrly loss attributable $9.8 mln
Wednesday, 24 May 2017 07:09pm EDT 

May 25 (Reuters) - Mesoblast Ltd ::Qtrly loss attributable to owners of Mesoblast limited $9.8 million versus loss of $16.9 million.Q3 revenue $901,000 versus $4.1 million."There is uncertainty related to the group’s ability to partner programs and raise capital at terms to meet the group’s requirements"."Uncertain related to group’s ability to sustainably implement planned cost reductions and defer programs on timely basis while achieving expected outcomes".  Full Article

Mesoblast receives A$3.7m from Australian Government for research and development
Wednesday, 5 Apr 2017 07:33pm EDT 

Mesoblast Ltd :Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX.  Full Article

FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy
Monday, 3 Apr 2017 04:34pm EDT 

Mesoblast Ltd :FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease.  Full Article

IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial
Friday, 31 Mar 2017 06:00am EDT 

Mesoblast Ltd : Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial . Says interim analysis dataset has been locked and will be analyzed and reviewed by trial's independent statisticians . Mesoblast Ltd - throughout review process, co to remain blinded to individual treatment allocation as well as grouped safety and efficacy data .Mesoblast Ltd - IDMC will review and interpret results of interim analysis and provide recommendations shortly.  Full Article

Mesoblast raises US$40 million
Sunday, 26 Mar 2017 07:40pm EDT 

Mesoblast Ltd : Mesoblast raises US$40 million .Placement price of A$2.00 per share represents a 4.8 pct discount to 15 day vwap of A$2.10.  Full Article

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage: